ASAnna Schuh

Anna Schuh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Schuh has a total of 697 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A qualitative evidence synthesis on perinatal screening for sickle cell disease in high-burden countries

    by Amelia Seabold, Alina Luchyshyn, Nia Roberts, Anna Schuh, Lulu Chirande, Helene-Mari van der Westhuizen

  • Open Access

    Bridging the diagnostic gap in CLL through TP53 molecular diagnostics in sub-Saharan Africa

    by Collin Nzunda, Doreen Kamori, Ahlam Nasser, Clara Chamba, Eliud Buchard, Jeffer Bhuko, Heavenlight Christopher, Emmanuel Saukiwa, Caroline Mollel, Antony Cutts, et al.


  • Open Access

    Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone as First-Line Therapy for Patients With Diffuse Large B-Cell Lymphoma

    by Andrew J. Davies, Louise Stanton, Joshua Caddy, Nicola Campbell, Graham P. Collins, Katy McLaughlin, Christopher Wignall, Geoff N. Saunders, Christopher P. Fox, Robert Waugh, et al.

    PURPOSE: Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The ACCEPT trial investigated the safety and efficacy of acalabrutinib in addition to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) in first-line therapy. METHODS: In this phase Ib/II non-randomized study, eligible patients were treatment naïve, aged 16 years or older with a histologic diagnosis of DLBCL. The primary end point of the trial was to determine the recommended phase II dose (RP2D) of acalabrutinib in combination with R-CHOP and assess the safety and overall response rate (ORR). RESULTS: Between 2017 and 2020, 38 patients were enrolled. Of those enrolled, seven were ineligible. Median age was 64 years (range, 24-80); 76% were stage III/IV; 55% International Prognostic Index ≥3. No dose-limiting toxicities were observed, and the RP2D of acalabrutinib was 100 mg twice daily. The most common grade ≥3 adverse events at RP2D were neutropenia (37%), febrile neutropenia (13%), and diarrhea (10%). Eighty-eight percent of patients received six cycles of R-CHOP. Age did not compromise treatment delivery. At the RP2D, 20/24 (83%) patients had a complete response and three (12.5%) a partial response (ORR, 96% [95% CI, 79 to 100]). With median 30-months follow-up, the 24-month progression-free survival was 95% (95% CI, 68 to 99), event-free survival was 90% (95% CI, 66 to 97), and overall survival was 96% (95% CI, 73 to 99). CONCLUSION: The combination of acalabrutinib with R-CHOP is well tolerated, including in those older than 65 years. High efficacy in DLBCL was observed, regardless of cell-of-origin subtype. These findings support further investigation of this combination in a randomized trial.

  • Open Access

    Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas

    by Clara Chamba, Heavenlight Christopher, Emmanuel Josephat, Julius Sseruyange, Alisen Ayitewala, Kieran Howard, Helene Dreau, Adam Burns, Ismail Legason, Isaac Otim, et al.

    Burkitt’s lymphoma (BL) is common in sub-Saharan Africa, yet diagnosis is often delayed due to limited pathology capacity. Here we evaluated blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma at four hospitals in Tanzania and Uganda, assessing diagnostic accuracy and turnaround time (TAT). After extensive pathology capacity building, a gold-standard diagnosis was established using tissue morphology, a limited validated immunohistochemistry panel and independent dual histopathologist review. Using clinical features and circulating tumor DNA markers ( MYC mutations, MYC –immunoglobulin translocations and Epstein–Barr virus fragmentomics), we trained six penalized logistic regression models with tenfold crossvalidation ( n = 212). The best-performing model was externally validated in a prospective real-world cohort ( n = 56). Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants. The comprehensive model achieved the highest performance (area under the curve (AUC) 0.95, 95% confidence interval (95% CI) 0.901–0.981, sensitivity 0.86, specificity 0.95), confirmed by external validation (AUC 0.98, 95% CI 0.942–1.000). Liquid biopsy was the only diagnostic result available at the multidisciplinary review in 42% of participants and reduced median diagnostic TAT from 46.8 d to 6.5 d ( P = 4.42 × 10 −10 ). These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV + BL and may substantially reduce treatment delays in resource-limited settings.


  • Open Access

    Response rate and survival of patients with chronic-phase chronic myeloid leukemia on second-line treatment in Tanzania

    by Ahlam Nasser, Elia J. Mmbaga, Hamisa Iddy, Caroline Mollel, Collin Nzunda, Ismail Mwaruka, Rehema Shungu, Ally Hussein, Neil Dunavin, Katherine Van Loon, et al.


  • Open Access

    High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights

    by H. Parker, L. Carr, K. Norris, A. Nilsson-Takeuchi, B. Stevens, H. Amarasinghe, L. Kadalayil, M. Else, R. Clifford, A. Pettitt, et al.

    High genomic complexity (HGC) is linked to poor prognosis in CLL, but its independent prognostic value remains uncertain amid emerging biomarkers. We analysed copy number alterations (CNA) in 495 untreated patients from (immuno)chemotherapy trials (CLL4, ADMIRE, ARCTIC), incorporating IGHV status, telomere length (TL), targeted sequencing and DNA-methylation subtypes. Patients harboured low (LGC, ≤2 CNAs; n = 334), intermediate (IGC, 3–4 CNAs; n = 97), or high (HGC, ≥5 CNAs; n = 64) genomic complexity. HGC associated with U-CLL (81%, p < 0.001), TP53 -aberration (36%, p < 0.001), short TL (TL-S; 61%, p < 0.05), del13q (50%, p < 0.001) and del11q (22%, p < 0.05). IGC was enriched for biallelic ATM disruption and BIRC3 deletions ( p < 0.001). Trisomy 12 and NOTCH1 mutations were enriched in LGC ( p < 0.001). HGC associated with shorter progression-free and overall survival in univariate models but only remained independent for OS in CLL4 (HR = 1.61, p = 0.02). Independent prognostic factors included TP53 aberration, U-CLL, TL-S and n-CLL. Of 64 HGC patients, 23 had TP53 -aberration; 92% of TP53 wild-type cases had other high-risk features (TL-S, U-CLL, or n-CLL). HGC may reflect a convergence of high-risk features rather than represent an independent biomarker. The interplay of telomere attrition, IGHV status and DNA methylation subtype necessitates further validation in targeted therapy cohorts to enhance risk assessment in prognostic models.

  • Open Access

    Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania

    by Jingjing Jiang, Liz Morrell, Malale Tungu, William F. Mawalla, Clara Chamba, Lulu Chirande, Heronima J. Kashaigili, Elifuraha Mkwizu, Paul S. Ntemi, Godlove Sandi, et al.

    Background: Burkitt Lymphoma (BL) is a prevalent and highly aggressive childhood cancer in sub-Saharan Africa (SSA). Outcomes are poor, due in part to delays or inaccuracies in diagnosis. Liquid biopsy (sequencing circulating tumour DNA from blood) is an alternative approach that is non-invasive and offers potential for a highly specific, rapid diagnosis, which could improve outcomes through earlier access to correct treatment. Diagnosis by liquid biopsy has undergone validation in SSA. However, evidence on its economic value is needed, especially in limited-resource settings. We present a cost-utility analysis comparing liquid biopsy with conventional local histopathology for the diagnosis of paediatric BL in Tanzania. Methods: A cost-utility model was constructed to compare the costs and effects of the alternative diagnostic approaches from a Tanzanian healthcare provider perspective, over a lifetime horizon. For the liquid biopsy, we assumed testing at the patient’s first contact with healthcare, resulting in earlier diagnosis. Resource use and outcome data were taken from the Aggressive Infection-Related East Africa Lymphoma study. Health outcomes were measured in Disability-Adjusted Life Years (DALYs). Costs and outcomes were discounted at 5%. Probabilistic and univariate sensitivity analyses and scenario analysis were conducted. Results: Diagnosis by liquid biopsy results in a reduced burden of 9.4 DALYs per patient compared to 10.5 for histopathology (difference 1.11 DALYs, 95% confidence interval 0.13–2.06), and per-patient costs are $1978 higher (95% CI $1299–2840), due to greater diagnosis costs. The incremental cost-effectiveness ratio (ICER) is $1778 per DALY averted. Probabilistic sensitivity analysis indicates that liquid biopsy is more likely to be cost-effective than pathology, at any threshold above $1890/DALY averted. The ICER is sensitive to assumptions regarding the extent of disease advancement at the earlier diagnosis, and to discount rate and diagnosis costs. Conclusions: Diagnosis by liquid biopsy could be cost-effective when used to accelerate diagnosis of BL in children and young adults in Tanzania, depending on when it is implemented in the patient journey, model assumptions and the decision threshold chosen. Trial registration: Pan African Clinical Trials Registry: PACTR202204822312651, registered on 14th April 2022.


  • Open Access

    A call to standardize the definition of countries with a high-burden of sickle cell disease

    by Amelia Seabold, Igor Rudan, Jemma M Houghton, Lulu Chirande, Anna Schuh, Helene-Mari van der Westhuizen


  • Open Access

    Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology

    by Dylan Domenico, Gunes Gundem, Max F. Levine, Juan Esteban Arango-Ossa, Pauline Robbe, Georgios Asimomitis, Cassidy Cobbs, Emily Stockfisch, Tara O’donohue, Charlotte Brierley, et al.

    The adoption of whole genome sequencing (WGS) in clinical oncology is challenged by low data quality and increased artifacts in standard-of-care formalin-fixed paraffin-embedded (FFPE) samples. Analysis of 56 fresh frozen (FF) and FFPE matched pairs demonstrates that FFPE processing results in a median 20-fold enrichment in artifactual calls across mutation classes and impairs detection of clinically relevant biomarkers such as homologous recombination deficiency (HRD). We demonstrate that implementation of consensus calling reduces artifactual structural variant (SV) calls by 98% but is not sufficient in mitigating artifactual calls for single nucleotide variants (SNVs) and indels as compared to FF data. We develop FFPErase, a machine learning framework that filters SNV/indel artifacts and delivers clinical grade variant reporting allowing accurate quantification of clinically relevant biomarkers. Comparison of FFPErase WGS calls to clinical reporting by FDA-approved panel tests demonstrates 99% sensitivity and enables reporting of 24% more clinically relevant findings.


  • Open Access

    Artificial intelligence in breast cancer diagnosis: A systematic literature review

    by Arslaan Javaeed, Anna Schuh

    Breast cancer is the second leading cause of cancer-related deaths among women globally and the most prevalent cancer in women. Artificial intelligence (AI)-based frameworks have shown great promise in correctly classifying breast carcinomas, particularly those that may have been difficult to discern through routine microscopy. Additionally, mitotic number quantification utilizing AI technology is more accurate than manual counting. With its many advantages, such as improved accuracy, efficiency and consistency as shown in this literature review, AI has promise for significantly enhancing breast cancer diagnosis in the clinical world despite the paramount obstacles that must be addressed. Ongoing research and innovation are essential for overcoming these challenges and effectively harnessing AI’s transformative potential in breast cancer detection and assessment.